The authors write that once severe asthma is diagnosed, clinicians should determine asthma endotype (Type2-high or Type2-low) to help choose the best therapy for the patient.
The approval of Yonsa was based on 2 randomized, placebo-controlled, multicenter Phase 3 studies in patients with mCRPC.
Subcutaneous dupilumab significantly reduced the use of oral corticosteroids in patients with corticosteroid-dependent severe asthma.
Peak expiratory flow increases were greater with benralizumab than placebo in patients with severe eosinophilic asthma.
The authors reported that ACQ scores (P=0.04) and oral corticosteroid use (P=0.04) were significantly reduced in high severity completers (n=21) receiving escitalopram.
Children with asthma who experience chronic oral glucocorticoid exposure may have significant morbidities, including adrenal suppression, recurrent pneumonia, and behavioral problems.
Reslizumab reduced the risk for exacerbations and improved lung function when compared to placebo, in patients with severe eosinophilic asthma.
Drugs in the Pipeline
The disease can be life threatening. Phase 3 study results released last March demonstrated Rituxan substantialy improved pemphigus vulgaris remission rates and successful tapering.
Both the 60- and 120-actuation sizes have been discontinued.
EGPA (formerly known as Churg-Strauss syndrome) is a condition characterized by asthma, high levels of eosinophils (a type of white blood cell that helps fight infection), and inflammation of small- to medium-sized blood vessels.